The Bioprinting Cluster is an informal network of Horizon Europe projects funded under the topic Bio-printing of living cells for regenerative medicine (HORIZON-HLTH-2024-TOOL-11-02). Through the cluster, the projects exchange knowledge at executive level, align communication and dissemination activities, and look for opportunities to work together on shared challenges, such as regulatory pathways and manufacturing.
LUMINATE is proud to be part of this network. Discover our sister projects.
Advanced 4D printing technologies in corneal regeneration: a pathway to restored vision
Corneal blindness affects more than 11.7 million people worldwide, yet only about 1 in 70 patients who need a corneal transplant receives one. KeratOPrinter aims to develop a 4D bioprinting suite, centred around regenerative medicine and tissue engineering, that can deliver a fully functional, biocompatible, full-thickness native-like human cornea. The project combines stem cell-derived cells, multi-material bioinks that mimic the cornea’s natural matrix, and high-precision printing with in-process monitoring. The aim is to enable millions of people to receive vision-saving therapy.
Innovative in situ 4D bioprinting for regeneration of colorectal mucosa and submucosa
Colorectal diseases are currently treated with invasive surgery that can have significant long-term consequences for patients. TENTACLE aims to develop a minimally invasive, regenerative therapy based on in situ 4D bioprinting, enabling the repair and regeneration of colorectal mucosa and submucosa directly within the body. By integrating advanced biomaterials, tissue engineering and colonoscopic technologies, the project seeks to provide patient-specific solutions that reduce surgical burden and improve quality of life. Partners across Europe work together to make these approaches clinically and regulatorily viable.
A bioprinting platform for patterning cellular aggregates and microtissues into macroscale regenerative grafts
m2M is developing a new bioprinting platform that patterns cellular aggregates and microtissues into scaled-up, personalised, load-bearing grafts, and guides their remodelling into fully functional tissue in the body. The project combines microtissues with advanced bioinks and melt electrowritten scaffolds, using sensor-equipped printheads and a GMP-ready process. m2M will bioprint osteochondral and maxillofacial grafts and test their regenerative potential, with the aim of helping patients at risk of knee osteoarthritis and strengthening European biomanufacturing.
Automated generation of dense, functional and perfusable bioprinted liver constructs for transplantation
There are not enough donor organs for everyone who needs a transplant. NEOLIVER aims to develop personalised, bioprinted liver constructs using a patient’s own cells, offering a sustainable alternative to traditional organ donation. By combining advanced biotechnologies, automation and manufacturing processes, the project seeks to make organ biofabrication more scalable and clinically relevant. Universities, research centres, SMEs and clinical partners from across Europe work together to deliver innovative solutions with strong medical and societal impact.
Strategies for optimised bioprinting of next generation tissues for urethral regeneration and translation
Urethral strictures affect a significant proportion of the male population, causing lasting physical, psychological and economic harm, while effective repair options remain scarce. STRONG-UR combines novel manufacturing technologies and biomaterials to create viable, personalised tissue constructs for tubular organs, starting with the urethra. The project develops modular bioprinter components and smart hydrogel bioinks, and follows two routes to the clinic: single-stage in situ bioprinting, and a multistage approach using GMP-manufactured components to support vascularisation and healing.